Innate Pharma: abstract on IPH45 at the AACR congress
IPH45 is a novel antibody conjugate targeting nectin-4 -a cell membrane adhesion protein overexpressed in several solid tumors- and differentiated with a topoisomerase I inhibitor as a cytotoxic agent.
Our studies demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and has a favorable safety profile in preclinical studies", emphasizes Eric Vivier, Chief Scientific Officer of Innate Pharma.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction